Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02175628 · ClinicalTrials.gov registry record · NA
Comparison of the Sensitivity and Specificity of Acoustic Angiography to the Sensitivity and Specificity of Conventional Ultrasound
A NA study of Signs and Symptoms, sponsored by UNC Lineberger Comprehensive Cancer Center.
- Completed
- Registry status
- NA
- Development phase
- 23
- Enrollment target
- 1
- Study location
NCT02175628 is a NA study of Signs and Symptoms that has completed, run by UNC Lineberger Comprehensive Cancer Center. The registered enrollment target is 23 participants, below the 165-participant average among 6 other Signs and Symptoms trials with a reported enrollment target (86% lower). The trial reports 1 study location across 1 state.
The verdict
NCT02175628, a NA study of Signs and Symptoms, has completed, sponsored by UNC Lineberger Comprehensive Cancer Center.
- COMPLETED
- Registry status
- NA
- Development phase
- 23 participants
- Enrollment target
- 1
- Study location
Study Summary
Purpose: This study will evaluate a new ultrasound imaging technology called acoustic angiography. Acoustic angiography uses an ultrasound contrast agent, already FDA approved for use in cardiology, to enhance imaging of blood vessels. Since acoustic angiography uses ultrasound, and not x-rays, the patient is not exposed to ionizing radiation, unlike traditional angiography and mammography. Specific goals will be to evaluate the quality of the images provided by acoustic angiography in the human breast, and furthermore to evaluate whether or not acoustic angiography provides additional diagnostic information over traditional ultrasound which could provide an improvement in assessing breast lesions. Specifically, this additional diagnostic information will hopefully enable us to reduce false positive tests and discriminate lethal cancers from non-lethal disease. Participants: The investigators are recruiting 60 patients from the UNC Breast Clinic who are undergoing core needle biopsy or surgical biopsy (BIRADS 4 and 5 breast lesions). Procedures (methods): Acoustic Angiography imaging will be performed in conjunction with standard diagnostic imaging, including b-mode ultrasound . Then, a reader study will be conducted to compare these modalities. Finally, the images will be analyzed with image processing techniques to determine quantitative metrics exhibited by the blood vessel morphology in the images. These metrics will be utilized to develop a "malignancy score" equation to predict malignancy of a lesion.
Conditions Studied
Interventions
- DEVICE Acoustic Angiography
Study Locations (1)
North Carolina
- UNC Hospital - Chapel Hill
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2014-06 |
| Est. Completion | 2018-06-30 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02175628
The ClinicalTrials.gov registry entry for NCT02175628 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 23 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 165-participant average among 6 other Signs and Symptoms trials with a reported enrollment target (86% lower). The listed sponsor is UNC Lineberger Comprehensive Cancer Center, which has 366 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Signs and Symptoms appearing as the primary indexed condition, and to 1 intervention - of which Acoustic Angiography is the first listed.
NCT02175628 reports 1 study location spanning 1 distinct geographic area - top geographies include North Carolina.
Frequently Asked Questions
What is clinical trial NCT02175628 about?
NCT02175628 is a clinical study titled "Comparison of the Sensitivity and Specificity of Acoustic Angiography to the Sensitivity and Specificity of Conventional Ultrasound". Purpose: This study will evaluate a new ultrasound imaging technology called acoustic angiography. Acoustic angiography uses an ultrasound contrast agent, already FDA approved for use in cardiology, to enhance imaging of blood vessels. Since acoustic angiography uses ultrasound, and not x-rays, the ...
What is the current status of trial NCT02175628?
This trial is currently completed. It is a NA study. The enrollment target is 23 participants. The study started on 2014-06. Estimated completion is 2018-06-30.
What conditions does trial NCT02175628 study?
This clinical trial studies the following conditions: Signs and Symptoms.
What interventions are being tested in trial NCT02175628?
The interventions under investigation include: Acoustic Angiography (DEVICE).
Who is sponsoring clinical trial NCT02175628?
This trial is sponsored by UNC Lineberger Comprehensive Cancer Center, which has 366 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02175628 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Signs and Symptoms
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Tolerability and Functional Assessment of a Novel Children's Synbiotic
COMPLETED · NA
-
Examine the Effects of Meditation on Daily Psychological Stress Responses in Woman With a History of Child Adversity
COMPLETED · NA
-
Validity and Inter-Rater Reliability of a Novel Bedside Referral Tool for Spasticity
COMPLETED
-
Distributed Registry
COMPLETED
-
Using Telemedicine to Improve Spasticity Diagnosis Rates
COMPLETED
-
Help Veterans Experience Less Pain Study (HELP-Vets)
COMPLETED
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.